JP2015522266A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015522266A5 JP2015522266A5 JP2015519082A JP2015519082A JP2015522266A5 JP 2015522266 A5 JP2015522266 A5 JP 2015522266A5 JP 2015519082 A JP2015519082 A JP 2015519082A JP 2015519082 A JP2015519082 A JP 2015519082A JP 2015522266 A5 JP2015522266 A5 JP 2015522266A5
- Authority
- JP
- Japan
- Prior art keywords
- vaccine
- oligodeoxynucleotide
- antigen component
- carrier
- tcg
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 229960005486 vaccines Drugs 0.000 claims 3
- 239000000427 antigen Substances 0.000 claims 2
- 102000038129 antigens Human genes 0.000 claims 2
- 108091007172 antigens Proteins 0.000 claims 2
- 239000000969 carrier Substances 0.000 claims 1
- 201000009910 diseases by infectious agent Diseases 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000003308 immunostimulating Effects 0.000 claims 1
- 150000007523 nucleic acids Chemical class 0.000 claims 1
- 108020004707 nucleic acids Proteins 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 description 1
Description
[gacgtt]n、ここで、n>=4
[gacgatcgtc]n、ここで、n>=3
[tcgtcgttttcg]n、ここで、n>=3
[tcgtcgttgtcgttttgtcgtt]n、ここで、n>=2
(tx[ttcgtt]ty)n、ここで、n>=5,x=0−5およびy=0−5[ttcgtN1]n、ここで、N1=tまたはc、およびn>=5
[N1tcgtc]n、ここで、N1=tまたはc、およびn>=5
[gN1cgtt]n、ここで、n>=4およびN1=aまたはt
[tcg]x、ここで、n>=6
[tcgN1]n、ここで、N1=cまたはg、およびn>=6
[N1cgt]n、ここで、N1=gまたはcまたはaまたはt、およびn>=6
[acga]n、ここで、n>=6。
[gacgatcgtc]n、ここで、n>=3
[tcgtcgttttcg]n、ここで、n>=3
[tcgtcgttgtcgttttgtcgtt]n、ここで、n>=2
(tx[ttcgtt]ty)n、ここで、n>=5,x=0−5およびy=0−5[ttcgtN1]n、ここで、N1=tまたはc、およびn>=5
[N1tcgtc]n、ここで、N1=tまたはc、およびn>=5
[gN1cgtt]n、ここで、n>=4およびN1=aまたはt
[tcg]x、ここで、n>=6
[tcgN1]n、ここで、N1=cまたはg、およびn>=6
[N1cgt]n、ここで、N1=gまたはcまたはaまたはt、およびn>=6
[acga]n、ここで、n>=6。
全般的には、オリゴデオキシヌクレオチドの活性は、nが増加するにつれて増加することが見出された。この効果は、nが増加するにつれて一様になる。したがって、基本的には、バックボーン構造の数nは、少なくとも示されているnの数であるべきである。好ましくは、nの高域範囲はn<=100である。これは、単に、合成配列が長くなればなるほど製造が困難になるからである。したがって、実際には、より好ましいnの高域範囲はn<=40、より一層好ましくは、n<=20である。
Claims (1)
- 感染症の予防または抑制のためのワクチンであって、該ワクチンは、一般式[tcg]n(ここで、n>=6)を有する免疫刺激性非メチル化PTOオリゴデオキシヌクレオチドまたは担体もしくはハプテンに結合した当該オリゴデオキシヌクレオチド、抗原成分または抗原成分をコードする核酸、および医薬上許容される担体を含む、前記ワクチン。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP12174199 | 2012-06-28 | ||
EP12174199.5 | 2012-06-28 | ||
PCT/EP2013/063452 WO2014001422A2 (en) | 2012-06-28 | 2013-06-27 | Toll-like receptors |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2015522266A JP2015522266A (ja) | 2015-08-06 |
JP2015522266A5 true JP2015522266A5 (ja) | 2017-02-09 |
JP6427487B2 JP6427487B2 (ja) | 2018-11-21 |
Family
ID=48699818
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2015519082A Expired - Fee Related JP6427487B2 (ja) | 2012-06-28 | 2013-06-27 | Toll様受容体 |
Country Status (14)
Country | Link |
---|---|
US (1) | US10112985B2 (ja) |
EP (1) | EP2867249B1 (ja) |
JP (1) | JP6427487B2 (ja) |
KR (1) | KR20150023465A (ja) |
CN (1) | CN104718221B (ja) |
AR (1) | AR091569A1 (ja) |
AU (1) | AU2013283359A1 (ja) |
CA (1) | CA2873288A1 (ja) |
ES (1) | ES2673899T3 (ja) |
MX (1) | MX2014015766A (ja) |
NZ (1) | NZ701803A (ja) |
RU (1) | RU2015102611A (ja) |
WO (1) | WO2014001422A2 (ja) |
ZA (1) | ZA201408773B (ja) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108472255A (zh) * | 2015-06-26 | 2018-08-31 | 拜耳动物保健有限责任公司 | 调节胞质dna监测分子的方法 |
EP3468605A4 (en) | 2016-06-08 | 2020-01-08 | President and Fellows of Harvard College | MODIFIED VIRAL VECTOR REDUCING THE INDUCTION OF INFLAMMATORY AND IMMUNE RESPONSES |
US11981911B2 (en) | 2017-11-08 | 2024-05-14 | President And Fellows Of Harvard College | Compositions and methods for inhibiting viral vector-induced inflammatory responses |
CR20200260A (es) * | 2017-12-15 | 2020-08-01 | Bayer Animal Health Gmbh | Composiciones inmunoestimulantes |
WO2019195285A1 (en) * | 2018-04-02 | 2019-10-10 | University Of Miami | Ifn-beta reporter system for immortalized primary cells |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7696338B2 (en) * | 1995-10-30 | 2010-04-13 | The United States Of America As Represented By The Department Of Health And Human Services | Immunotoxin fusion proteins and means for expression thereof |
US5948677A (en) | 1996-12-09 | 1999-09-07 | Jarvik; Jonathan W. | Reading frame independent epitope tagging |
EP1259264A4 (en) * | 2000-02-23 | 2005-08-31 | Univ California | METHOD FOR THE TREATMENT OF INFLAMMATORY ENDURANCE AND OTHER FORMS OF GASTROINTESTINAL DEFICIENCY |
US20040131628A1 (en) * | 2000-03-08 | 2004-07-08 | Bratzler Robert L. | Nucleic acids for the treatment of disorders associated with microorganisms |
CN1271733A (zh) * | 2000-04-04 | 2000-11-01 | 中国预防医学科学院病毒学研究所 | 对人免疫细胞有特异免疫刺激活性的CpG寡核酸 |
SE0201701D0 (sv) * | 2002-06-05 | 2002-06-05 | Gotovax Ab | Treatment of epithelial tumors and infections |
AR040996A1 (es) | 2002-08-19 | 2005-04-27 | Coley Pharm Group Inc | Acidos nucleicos inmunoestimuladores |
AU2003278845A1 (en) | 2002-09-19 | 2004-04-08 | Coley Pharmaceutical Gmbh | Toll-like receptor 9 (tlr9) from various mammalian species |
JPWO2005001116A1 (ja) * | 2003-06-17 | 2006-08-24 | 明治乳業株式会社 | Toll様レセプター強制発現細胞の利用 |
JP3976742B2 (ja) * | 2004-02-27 | 2007-09-19 | 江守商事株式会社 | インターフェロンアルファを誘導する免疫刺激オリゴヌクレオチド |
US7647679B2 (en) | 2007-07-03 | 2010-01-19 | Hardinge, Inc. | Belt-driven indexing tool turret assembly |
FR2954703B1 (fr) * | 2009-12-28 | 2013-12-13 | Chu Nantes | Agonistes des recepteurs tlr 4 et 9 pour prevenir les complications septiques de l'immunodepression post-traumatique chez les patients hospitalises pour traumatismes severes |
EP2471926A3 (en) * | 2010-12-30 | 2012-07-11 | Intervet International BV | Immunostimulatory oligodeoxynucleotides |
CA2834440A1 (en) | 2011-05-26 | 2012-11-29 | Intervet International B.V. | Immunostimulatory oligodeoxynucleotides |
BR112013029968A2 (pt) | 2011-05-26 | 2017-01-31 | Intervet Int Bv | oligodesoxinucleotídeo imunoestimulatório não metilado, vetor, vacina para prevenir ou combater uma doença infecciosa, e, método para a detecção de oligodesoxinucleotídeos imunoestimulatórios |
-
2013
- 2013-06-26 AR ARP130102257 patent/AR091569A1/es unknown
- 2013-06-27 WO PCT/EP2013/063452 patent/WO2014001422A2/en active Application Filing
- 2013-06-27 CA CA2873288A patent/CA2873288A1/en not_active Abandoned
- 2013-06-27 RU RU2015102611A patent/RU2015102611A/ru not_active Application Discontinuation
- 2013-06-27 CN CN201380033630.2A patent/CN104718221B/zh not_active Expired - Fee Related
- 2013-06-27 MX MX2014015766A patent/MX2014015766A/es unknown
- 2013-06-27 US US14/408,459 patent/US10112985B2/en active Active
- 2013-06-27 AU AU2013283359A patent/AU2013283359A1/en not_active Abandoned
- 2013-06-27 JP JP2015519082A patent/JP6427487B2/ja not_active Expired - Fee Related
- 2013-06-27 EP EP13731800.2A patent/EP2867249B1/en active Active
- 2013-06-27 ES ES13731800.2T patent/ES2673899T3/es active Active
- 2013-06-27 KR KR1020147036169A patent/KR20150023465A/ko not_active Application Discontinuation
- 2013-06-27 NZ NZ701803A patent/NZ701803A/en not_active IP Right Cessation
-
2014
- 2014-11-28 ZA ZA2014/08773A patent/ZA201408773B/en unknown
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2015522266A5 (ja) | ||
EP3681514A4 (en) | RNA VACZINE AGAINST ZIKA VIRUS | |
PT2121011E (pt) | Vacinas compreendendo um antigénio a partir de quatro estirpes do vírus da gripe | |
IL203869A (en) | Method of Preparing a Containing a Virus or Antigen Antigen, Various Aspects Related to This Method, Uses of a Method and Vaccination of a Split Virus Prepared by This Method | |
EP2670443A4 (en) | NUCLEIC ACID MOLECULES ENCODING NEW HERPES ANTIGENS, VACCINE COMPRISING THE SAME, AND METHODS OF USING SAME | |
EP4279610A3 (en) | Ribonucleic acid purification | |
DK2519266T3 (da) | Infektiøse DNA vacciner mod Chikungunya virus | |
BR112015022522A2 (pt) | engenharia de genomas de planta usando sistemas crispr/cas | |
BRPI0716536A2 (pt) | produÇço de vacinas de vÍrus influenza, sem a utilizaÇço de ovos | |
JP2016513638A5 (ja) | ||
BR112013029968A2 (pt) | oligodesoxinucleotídeo imunoestimulatório não metilado, vetor, vacina para prevenir ou combater uma doença infecciosa, e, método para a detecção de oligodesoxinucleotídeos imunoestimulatórios | |
WO2012027365A3 (en) | Targeted multi-epitope dosage forms for induction of an immune response to antigens | |
ZA201309386B (en) | Vaccine composition comprising an inactivated chikungunya virus strain | |
EP4043031A3 (en) | Zika viral antigen constructs | |
BR112013029966A2 (pt) | oligodesoxinucleotídeo imunoestimulatório não metilado, vetor, e, vacina para prevenir ou combater uma doença infecciosa | |
UA108902C2 (uk) | Вірус північноамериканського репродуктивного та респіраторного синдрому свиней (prrs) та його застосування | |
EP2836505A4 (en) | HUMAN RESPIRATORY SYNZYTIALVIRUS CONSENSUS ANTIGENES, NUCLEIC ACIDIC CONSTRUCTS AND VACCINES THEREOF AND METHOD OF USE THEREOF | |
BR112014001049A2 (pt) | método para a produção de um antígeno viral derivado de vírus envelopado, e, uso de um método para a fabricação de uma preparação de vacina contendo o antígeno viral | |
BRPI0811499A2 (pt) | Métodos para purificar um vírus ou antígeno viral, e para preparar uma vacina contra um vírus ou antígeno viral. | |
WO2014124238A8 (en) | Attenuation of human respiratory syncytial virus by genome scale codon-pair deoptimization | |
JP2012202968A5 (ja) | ||
PL2992005T3 (pl) | Zmutowane białko wypustek rozszerzające tropizm tkankowy wirusa zakaźnego zapalenia oskrzeli (IBV) | |
ES2673899T3 (es) | Receptores de tipo toll y oligonucleótidos inmunoestimuladores | |
WO2014140166A3 (en) | Vaccine | |
EP3545083A4 (en) | VACCINES FOR INFECTIOUS DISEASES CAUSED BY POSITIVE-STRANDED RNA VIRUSES |